{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,24]],"date-time":"2026-03-24T09:07:07Z","timestamp":1774343227809,"version":"3.50.1"},"reference-count":47,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2011,1,25]],"date-time":"2011-01-25T00:00:00Z","timestamp":1295913600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2011,1,25]],"date-time":"2011-01-25T00:00:00Z","timestamp":1295913600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Pharmacogenomics J"],"published-print":{"date-parts":[[2012,6]]},"DOI":"10.1038\/tpj.2010.93","type":"journal-article","created":{"date-parts":[[2011,1,25]],"date-time":"2011-01-25T14:08:45Z","timestamp":1295964525000},"page":"260-266","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":24,"title":["Association study of Cannabinoid receptor 1 (CNR1) gene in tardive dyskinesia"],"prefix":"10.1038","volume":"12","author":[{"given":"A K","family":"Tiwari","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"C C","family":"Zai","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"O","family":"Likhodi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A N","family":"Voineskos","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"H Y","family":"Meltzer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J A","family":"Lieberman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S G","family":"Potkin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"G","family":"Remington","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"D J","family":"M\u00fcller","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J L","family":"Kennedy","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2011,1,25]]},"reference":[{"key":"BFtpj201093_CR1","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1016\/0920-9964(91)90029-Q","volume":"4","author":"DE Casey","year":"1991","unstructured":"Casey DE . Neuroleptic drug-induced extrapyramidal syndromes and tardive dyskinesia. Schizophr Res 1991; 4: 109\u2013120.","journal-title":"Schizophr Res"},{"key":"BFtpj201093_CR2","doi-asserted-by":"publisher","first-page":"1581","DOI":"10.1016\/S0140-6736(03)13306-5","volume":"361","author":"S Leucht","year":"2003","unstructured":"Leucht S, Wahlbeck K, Hamann J, Kissling W . New generation antipsychotics versus low-potency conventional antipsychotics: a systematic review and meta-analysis. Lancet 2003; 361: 1581\u20131589.","journal-title":"Lancet"},{"key":"BFtpj201093_CR3","doi-asserted-by":"publisher","first-page":"279","DOI":"10.1192\/bjp.bp.108.050088","volume":"193","author":"DD Miller","year":"2008","unstructured":"Miller DD, Caroff SN, Davis SM, Rosenheck RA, McEvoy JP, Saltz BL et al. Extrapyramidal side-effects of antipsychotics in a randomised trial. Br J Psychiatry 2008; 193: 279\u2013288.","journal-title":"Br J Psychiatry"},{"key":"BFtpj201093_CR4","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1097\/YCO.0b013e3282f53132","volume":"21","author":"CU Correll","year":"2008","unstructured":"Correll CU, Schenk EM . Tardive dyskinesia and new antipsychotics. Curr Opin Psychiatry 2008; 21: 151\u2013156.","journal-title":"Curr Opin Psychiatry"},{"key":"BFtpj201093_CR5","doi-asserted-by":"publisher","first-page":"589","DOI":"10.1002\/mds.20823","volume":"21","author":"D Tarsy","year":"2006","unstructured":"Tarsy D, Baldessarini RJ . Epidemiology of tardive dyskinesia: is risk declining with modern antipsychotics? Mov Disord 2006; 21: 589\u2013598.","journal-title":"Mov Disord"},{"key":"BFtpj201093_CR6","doi-asserted-by":"publisher","first-page":"47","DOI":"10.3109\/10401230209147398","volume":"14","author":"J Gerlach","year":"2002","unstructured":"Gerlach J . Improving outcome in schizophrenia: the potential importance of EPS and neuroleptic dysphoria. Ann Clin Psychiatry 2002; 14: 47\u201357.","journal-title":"Ann Clin Psychiatry"},{"issue":"Suppl 1","key":"BFtpj201093_CR7","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1055\/s-2000-7672","volume":"33","author":"M Marsalek","year":"2000","unstructured":"Marsalek M . Tardive drug-induced extrapyramidal syndromes. Pharmacopsychiatry 2000; 33 (Suppl 1): 14\u201333.","journal-title":"Pharmacopsychiatry"},{"key":"BFtpj201093_CR8","doi-asserted-by":"publisher","first-page":"375","DOI":"10.1034\/j.1600-0447.2001.00401.x","volume":"104","author":"DJ Muller","year":"2001","unstructured":"Muller DJ, Schulze TG, Knapp M, Held T, Krauss H, Weber T et al. Familial occurrence of tardive dyskinesia. Acta Psychiatr Scand 2001; 104: 375\u2013379.","journal-title":"Acta Psychiatr Scand"},{"key":"BFtpj201093_CR9","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1038\/sj.tpj.6500233","volume":"4","author":"DJ Muller","year":"2004","unstructured":"Muller DJ, Shinkai T, De Luca V, Kennedy JL . Clinical implications of pharmacogenomics for tardive dyskinesia. Pharmacogenomics J 2004; 4: 77\u201387.","journal-title":"Pharmacogenomics J"},{"key":"BFtpj201093_CR10","doi-asserted-by":"publisher","first-page":"1285","DOI":"10.2217\/14622416.9.9.1285","volume":"9","author":"B Thelma","year":"2008","unstructured":"Thelma B, Srivastava V, Tiwari AK . Genetic underpinnings of tardive dyskinesia: passing the baton to pharmacogenetics. Pharmacogenomics 2008; 9: 1285\u20131306.","journal-title":"Pharmacogenomics"},{"key":"BFtpj201093_CR11","doi-asserted-by":"publisher","first-page":"923","DOI":"10.1038\/nm.f.1869","volume":"14","author":"I Katona","year":"2008","unstructured":"Katona I, Freund TF . Endocannabinoid signaling as a synaptic circuit breaker in neurological disease. Nat Med 2008; 14: 923\u2013930.","journal-title":"Nat Med"},{"key":"BFtpj201093_CR12","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1124\/mol.109.060251","volume":"77","author":"BD Hudson","year":"2010","unstructured":"Hudson BD, Hebert TE, Kelly ME . Ligand- and heterodimer-directed signaling of the CB(1) cannabinoid receptor. Mol Pharmacol 2010; 77: 1\u20139.","journal-title":"Mol Pharmacol"},{"key":"BFtpj201093_CR13","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1016\/j.ejphar.2003.08.101","volume":"480","author":"M van der Stelt","year":"2003","unstructured":"van der Stelt M, Di Marzo V . The endocannabinoid system in the basal ganglia and in the mesolimbic reward system: implications for neurological and psychiatric disorders. Eur J Pharmacol 2003; 480: 133\u2013150.","journal-title":"Eur J Pharmacol"},{"key":"BFtpj201093_CR14","doi-asserted-by":"publisher","first-page":"337","DOI":"10.1016\/j.neuroscience.2005.09.005","volume":"137","author":"F Matyas","year":"2006","unstructured":"Matyas F, Yanovsky Y, Mackie K, Kelsch W, Misgeld U, Freund TF . Subcellular localization of type 1 cannabinoid receptors in the rat basal ganglia. Neuroscience 2006; 137: 337\u2013361.","journal-title":"Neuroscience"},{"key":"BFtpj201093_CR15","doi-asserted-by":"publisher","first-page":"1029","DOI":"10.1111\/j.1476-5381.2008.00088.x","volume":"156","author":"J Fernandez-Ruiz","year":"2009","unstructured":"Fernandez-Ruiz J . The endocannabinoid system as a target for the treatment of motor dysfunction. Br J Pharmacol 2009; 156: 1029\u20131040.","journal-title":"Br J Pharmacol"},{"key":"BFtpj201093_CR16","doi-asserted-by":"publisher","first-page":"366","DOI":"10.1016\/0166-2236(89)90074-X","volume":"12","author":"RL Albin","year":"1989","unstructured":"Albin RL, Young AB, Penney JB . The functional anatomy of basal ganglia disorders. Trends Neurosci 1989; 12: 366\u2013375.","journal-title":"Trends Neurosci"},{"key":"BFtpj201093_CR17","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1016\/j.tins.2007.03.008","volume":"30","author":"DJ Surmeier","year":"2007","unstructured":"Surmeier DJ, Ding J, Day M, Wang Z, Shen W . D1 and D2 dopamine-receptor modulation of striatal glutamatergic signaling in striatal medium spiny neurons. Trends Neurosci 2007; 30: 228\u2013235.","journal-title":"Trends Neurosci"},{"key":"BFtpj201093_CR18","doi-asserted-by":"publisher","first-page":"543","DOI":"10.1016\/j.neuron.2008.11.005","volume":"60","author":"AC Kreitzer","year":"2008","unstructured":"Kreitzer AC, Malenka RC . Striatal plasticity and basal ganglia circuit function. Neuron 2008; 60: 543\u2013554.","journal-title":"Neuron"},{"key":"BFtpj201093_CR19","doi-asserted-by":"publisher","first-page":"5780","DOI":"10.1073\/pnas.96.10.5780","volume":"96","author":"A Zimmer","year":"1999","unstructured":"Zimmer A, Zimmer AM, Hohmann AG, Herkenham M, Bonner TI . Increased mortality, hypoactivity, and hypoalgesia in cannabinoid CB1 receptor knockout mice. Proc Natl Acad Sci USA 1999; 96: 5780\u20135785.","journal-title":"Proc Natl Acad Sci USA"},{"key":"BFtpj201093_CR20","doi-asserted-by":"publisher","first-page":"1667","DOI":"10.1038\/sj.npp.1301558","volume":"33","author":"AB Martin","year":"2008","unstructured":"Martin AB, Fernandez-Espejo E, Ferrer B, Gorriti MA, Bilbao A, Navarro M et al. Expression and function of CB1 receptor in the rat striatum: localization and effects on D1 and D2 dopamine receptor-mediated motor behaviors. Neuropsychopharmacology 2008; 33: 1667\u20131679.","journal-title":"Neuropsychopharmacology"},{"issue":"6 Part B","key":"BFtpj201093_CR21","doi-asserted-by":"publisher","first-page":"483","DOI":"10.1006\/nbdi.1998.0217","volume":"5","author":"F Rodriguez de Fonseca","year":"1998","unstructured":"Rodriguez de Fonseca F, Del Arco I, Martin-Calderon JL, Gorriti MA, Navarro M . Role of the endogenous cannabinoid system in the regulation of motor activity. Neurobiol Dis 1998; 5 (6 Part B): 483\u2013501.","journal-title":"Neurobiol Dis"},{"key":"BFtpj201093_CR22","doi-asserted-by":"publisher","first-page":"358","DOI":"10.1038\/7268","volume":"2","author":"A Giuffrida","year":"1999","unstructured":"Giuffrida A, Parsons LH, Kerr TM, Rodriguez de Fonseca F, Navarro M, Piomelli D . Dopamine activation of endogenous cannabinoid signaling in dorsal striatum. Nat Neurosci 1999; 2: 358\u2013363.","journal-title":"Nat Neurosci"},{"key":"BFtpj201093_CR23","doi-asserted-by":"publisher","first-page":"643","DOI":"10.1038\/nature05506","volume":"445","author":"AC Kreitzer","year":"2007","unstructured":"Kreitzer AC, Malenka RC . Endocannabinoid-mediated rescue of striatal LTD and motor deficits in Parkinson's disease models. Nature 2007; 445: 643\u2013647.","journal-title":"Nature"},{"key":"BFtpj201093_CR24","doi-asserted-by":"publisher","first-page":"848","DOI":"10.1126\/science.1160575","volume":"321","author":"W Shen","year":"2008","unstructured":"Shen W, Flajolet M, Greengard P, Surmeier DJ . Dichotomous dopaminergic control of striatal synaptic plasticity. Science 2008; 321: 848\u2013851.","journal-title":"Science"},{"key":"BFtpj201093_CR25","doi-asserted-by":"publisher","first-page":"639","DOI":"10.1017\/S1461145706007152","volume":"10","author":"CC Zai","year":"2007","unstructured":"Zai CC, Hwang RW, De Luca V, Muller DJ, King N, Zai GC et al. Association study of tardive dyskinesia and twelve DRD2 polymorphisms in schizophrenia patients. Int J Neuropsychopharmacol 2007; 10: 639\u2013651.","journal-title":"Int J Neuropsychopharmacol"},{"key":"BFtpj201093_CR26","doi-asserted-by":"publisher","first-page":"248","DOI":"10.1016\/j.schres.2008.08.036","volume":"106","author":"CC Zai","year":"2008","unstructured":"Zai CC, Romano-Silva MA, Hwang R, Zai GC, Deluca V, Muller DJ et al. Genetic study of eight AKT1 gene polymorphisms and their interaction with DRD2 gene polymorphisms in tardive dyskinesia. Schizophr Res 2008; 106: 248\u2013252.","journal-title":"Schizophr Res"},{"key":"BFtpj201093_CR27","doi-asserted-by":"publisher","first-page":"317","DOI":"10.1016\/j.euroneuro.2009.01.001","volume":"19","author":"CC Zai","year":"2009","unstructured":"Zai CC, Tiwari AK, De Luca V, Muller DJ, Bulgin N, Hwang R et al. Genetic study of BDNF, DRD3, and their interaction in tardive dyskinesia. Eur Neuropsychopharmacol 2009; 19: 317\u2013328.","journal-title":"Eur Neuropsychopharmacol"},{"key":"BFtpj201093_CR28","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1016\/j.pnpbp.2009.09.020","volume":"34","author":"CC Zai","year":"2010","unstructured":"Zai CC, Tiwari AK, Basile V, de Luca V, Muller DJ, Voineskos AN et al. Oxidative stress in tardive dyskinesia: genetic association study and meta-analysis of NADPH quinine oxidoreductase 1 (NQO1) and superoxide dismutase 2 (SOD2, MnSOD) genes. Prog Neuropsychopharmacol Biol Psychiatry 2010; 34: 50\u201356.","journal-title":"Prog Neuropsychopharmacol Biol Psychiatry"},{"key":"BFtpj201093_CR29","volume-title":"ECDEU Assessment Manual for Psychopharmacology","author":"W Guy","year":"1976","unstructured":"Guy W . ECDEU Assessment Manual for Psychopharmacology (revised edn.) Department of Health, Education and Welfare: Washington, DC, 1976."},{"key":"BFtpj201093_CR30","first-page":"486","volume":"39","author":"NR Schooler","year":"1982","unstructured":"Schooler NR, Kane JM . Research diagnoses for tardive dyskinesia. Arch Gen Psychiatry 1982; 39: 486\u2013487.","journal-title":"Arch Gen Psychiatry"},{"key":"BFtpj201093_CR31","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1016\/S0893-133X(98)00114-6","volume":"21","author":"VS Basile","year":"1999","unstructured":"Basile VS, Masellis M, Badri F, Paterson AD, Meltzer HY, Lieberman JA et al. Association of the MscI polymorphism of the dopamine D3 receptor gene with tardive dyskinesia in schizophrenia. Neuropsychopharmacology 1999; 21: 17\u201327.","journal-title":"Neuropsychopharmacology"},{"key":"BFtpj201093_CR32","first-page":"382","volume":"20","author":"J Lieberman","year":"1984","unstructured":"Lieberman J, Kane JM, Woerner M, Weinhold P, Basavaraju N, Kurucz J et al. Prevalence of tardive dyskinesia in elderly samples. Psychopharmacol Bull 1984; 20: 382\u2013386.","journal-title":"Psychopharmacol Bull"},{"issue":"Suppl","key":"BFtpj201093_CR33","doi-asserted-by":"publisher","first-page":"S54","DOI":"10.1007\/BF00442560","volume":"99","author":"J Lieberman","year":"1989","unstructured":"Lieberman J, Johns C, Cooper T, Pollack S, Kane J . Clozapine pharmacology and tardive dyskinesia. Psychopharmacology (Berl) 1989; 99 (Suppl): S54\u2013S59.","journal-title":"Psychopharmacology (Berl)"},{"key":"BFtpj201093_CR34","doi-asserted-by":"publisher","first-page":"5444","DOI":"10.1093\/nar\/19.19.5444","volume":"19","author":"DK Lahiri","year":"1991","unstructured":"Lahiri DK, Nurnberger Jr JI . A rapid non-enzymatic method for the preparation of HMW DNA from blood for RFLP studies. Nucleic Acids Res 1991; 19: 5444.","journal-title":"Nucleic Acids Res"},{"key":"BFtpj201093_CR35","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1002\/gepi.10252","volume":"25","author":"F Dudbridge","year":"2003","unstructured":"Dudbridge F . Pedigree disequilibrium tests for multilocus haplotypes. Genet Epidemiol 2003; 25: 115\u2013121.","journal-title":"Genet Epidemiol"},{"key":"BFtpj201093_CR36","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1093\/bioinformatics\/bth457","volume":"21","author":"JC Barrett","year":"2005","unstructured":"Barrett JC, Fry B, Maller J, Daly MJ . Haploview: analysis and visualization of LD and haplotype maps. Bioinformatics 2005; 21: 263\u2013265.","journal-title":"Bioinformatics"},{"key":"BFtpj201093_CR37","unstructured":"Gauderman WJ, Morrison JM . QUANTO 1.1: a computer program for power and sample size calculations for genetic-epidemiology studies, http:\/\/hydra.usc.edu\/gxe, 2006."},{"key":"BFtpj201093_CR38","doi-asserted-by":"publisher","first-page":"1315","DOI":"10.1038\/npp.2009.235","volume":"35","author":"AK Tiwari","year":"2010","unstructured":"Tiwari AK, Zai CC, Likhodi O, Lisker A, Singh D, Souza RP, et al. A common polymorphism in the cannabinoid receptor 1 (CNR1) gene is associated with antipsychotic-induced weight gain in Schizophrenia. Neuropsychopharmacology 2010; 35: 1315\u20131324.","journal-title":"Neuropsychopharmacology"},{"key":"BFtpj201093_CR39","doi-asserted-by":"publisher","first-page":"765","DOI":"10.1086\/383251","volume":"74","author":"DR Nyholt","year":"2004","unstructured":"Nyholt DR . A simple correction for multiple testing for single-nucleotide polymorphisms in linkage disequilibrium with each other. Am J Hum Genet 2004; 74: 765\u2013769.","journal-title":"Am J Hum Genet"},{"key":"BFtpj201093_CR40","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1038\/sj.hdy.6800717","volume":"95","author":"J Li","year":"2005","unstructured":"Li J, Ji L . Adjusting multiple testing in multilocus analyses using the eigenvalues of a correlation matrix. Heredity 2005; 95: 221\u2013227.","journal-title":"Heredity"},{"key":"BFtpj201093_CR41","doi-asserted-by":"publisher","first-page":"916","DOI":"10.1038\/sj.mp.4001560","volume":"9","author":"PW Zhang","year":"2004","unstructured":"Zhang PW, Ishiguro H, Ohtsuki T, Hess J, Carillo F, Walther D et al. Human cannabinoid receptor 1: 5\u2032 exons, candidate regulatory regions, polymorphisms, haplotypes and association with polysubstance abuse. Mol Psychiatry 2004; 9: 916\u2013931.","journal-title":"Mol Psychiatry"},{"key":"BFtpj201093_CR42","doi-asserted-by":"publisher","first-page":"2015","DOI":"10.1093\/emboj\/19.9.2015","volume":"19","author":"O Pabst","year":"2000","unstructured":"Pabst O, Forster R, Lipp M, Engel H, Arnold HH . NKX2.3 is required for MAdCAM-1 expression and homing of lymphocytes in spleen and mucosa-associated lymphoid tissue. EMBO J 2000; 19: 2015\u20132023.","journal-title":"EMBO J"},{"key":"BFtpj201093_CR43","doi-asserted-by":"publisher","first-page":"710","DOI":"10.1038\/ng.145","volume":"40","author":"SA Fisher","year":"2008","unstructured":"Fisher SA, Tremelling M, Anderson CA, Gwilliam R, Bumpstead S, Prescott NJ et al. Genetic determinants of ulcerative colitis include the ECM1 locus and five loci implicated in Crohn's disease. Nat Genet 2008; 40: 710\u2013712.","journal-title":"Nat Genet"},{"key":"BFtpj201093_CR44","doi-asserted-by":"publisher","first-page":"713","DOI":"10.1038\/ng.148","volume":"40","author":"A Franke","year":"2008","unstructured":"Franke A, Balschun T, Karlsen TH, Hedderich J, May S, Lu T et al. Replication of signals from recent studies of Crohn's disease identifies previously unknown disease loci for ulcerative colitis. Nat Genet 2008; 40: 713\u2013715.","journal-title":"Nat Genet"},{"key":"BFtpj201093_CR45","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1146\/annurev-genom-082908-150013","volume":"10","author":"J Van Limbergen","year":"2009","unstructured":"Van Limbergen J, Wilson DC, Satsangi J . The genetics of Crohn's disease. Annu Rev Genomics Hum Genet 2009; 10: 89\u2013116.","journal-title":"Annu Rev Genomics Hum Genet"},{"key":"BFtpj201093_CR46","doi-asserted-by":"crossref","first-page":"23390","DOI":"10.1016\/S0021-9258(19)49475-1","volume":"268","author":"B Andersen","year":"1993","unstructured":"Andersen B, Schonemann MD, Pearse II RV, Jenne K, Sugarman J, Rosenfeld MG . Brn-5 is a divergent POU domain factor highly expressed in layer IV of the neocortex. J Biol Chem 1993; 268: 23390\u201323398.","journal-title":"J Biol Chem"},{"key":"BFtpj201093_CR47","doi-asserted-by":"publisher","first-page":"1100","DOI":"10.1073\/pnas.0912710107","volume":"107","author":"T Hayashida","year":"2010","unstructured":"Hayashida T, Takahashi F, Chiba N, Brachtel E, Takahashi M, Godin-Heymann N et al. HOXB9, a gene overexpressed in breast cancer, promotes tumorigenicity and lung metastasis. Proc Natl Acad Sci USA 2010; 107: 1100\u20131105.","journal-title":"Proc Natl Acad Sci USA"}],"container-title":["The Pharmacogenomics Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/tpj201093.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/tpj201093","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/tpj201093.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,3,22]],"date-time":"2022-03-22T10:29:24Z","timestamp":1647944964000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/tpj201093"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,1,25]]},"references-count":47,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2012,6]]}},"alternative-id":["BFtpj201093"],"URL":"https:\/\/doi.org\/10.1038\/tpj.2010.93","relation":{},"ISSN":["1470-269X","1473-1150"],"issn-type":[{"value":"1470-269X","type":"print"},{"value":"1473-1150","type":"electronic"}],"subject":[],"published":{"date-parts":[[2011,1,25]]},"assertion":[{"value":"27 June 2010","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 October 2010","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 November 2010","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 January 2011","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"AKT\/CCZ\/DJM: report no competing interests. HYM has received grants or is a consultant to Abbott Labs, ACADIA, Bristol Myers Squibb, Eli Lilly, Janssen, Pfizer, Astra Zeneca, Glaxo Smith Kline, Memory, Cephalon, Minster, Aryx and BiolineRx. HYM is a shareholder of ACADIA. JAL reports that he serves on the Advisory Board of Bioline, GlaxoSmithKline, Intracellular Therapies, Eli Lilly, Pierre Fabre, Psychogenics and Wyeth. He does not receive financial compensation or salary support for his participation as an advisor. He receives grant support from Allon, Forest Labs, Merck and Pfizer; he holds a patent from Repligen. JLK has been a consultant to GSK, Sanofi-Aventis and Dainippon-Sumitomo.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}